The annual Corporate Reputation of Pharma survey for 2020 is unique in that the patient groups responding have the chance to comment on the industry’s performance during the pandemic.
Opinions of 1,920 patient groups on the performance of pharma in 2020 during the COVID-19 pandemic were collected, between November 2020 and February 2021, by PatientView.
"The effectiveness of pharma’s COVID-19 response, and its corporate reputation, were directly tied to one another"These groups reached out to more than one million patients, and overall their response to pharma’s effectiveness in tackling the pandemic was positive. Some 62% of the groups believed that the pharma industry as a whole was very effective or effective at tackling the pandemic for the patients known to them.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze